Vero Biotech is a biotechnology company that develops and commercializes innovative therapies for patients with rare diseases. The company's lead product candidate is a treatment for a rare genetic disorder called acute intermittent porphyria (AIP). Vero Biotech's therapy is designed to reduce the frequency and severity of AIP attacks. The company was founded in 2015 and is headquartered in Seattle, Washington.